Novo Nordisk to pay $2 billion for new weight loss drug
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a nascent ...
Software maker SAP unseats Novo Nordisk as Europe's largest company
German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market ...
Novo Nordisk Stock Rises Ahead of Data on Ozempic Ingredient's Ability to Lower Heart Risk
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...